For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Cipla's CEO Umang Vohra asserts that the US mandate for lowering prescription drug costs will not affect Indian generic ...

On May 13, 2025, numerous companies, including Bharti Airtel and Tata Motors, will release their financial results.

Cipla CEO Umang Vohra discusses US government's order on prescription drug prices, impact on generic drugmakers.

From significant investments to major deals, quarterly earnings, and acquisitions, here’s a quick look at which stocks will ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...